What is RSA?
RSA operates as an independent service provider for radiotherapy equipment, with a particular focus on external beam linear accelerators (LINACs). Since its inception in 1995, the North Carolina-based entity has been instrumental in supporting the oncology community. Its comprehensive service offerings span equipment life cycle management, essential maintenance, parts provision, and complex removals and installations, positioning RSA as a critical partner in maintaining the operational integrity of vital cancer treatment machinery.
How much funding has RSA raised?
RSA has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in RSA
PPP
Public-Private Partnership
What's next for RSA?
With substantial backing and a history of providing critical services to the oncology sector, RSA is well-positioned for continued expansion. The company's late-stage funding context suggests a focus on scaling operations, potentially through enhanced service capabilities, broader geographic reach, or strategic acquisitions. This strategic investment will likely enable RSA to further solidify its market leadership and meet the evolving demands of radiotherapy equipment management, ensuring reliable support for cancer treatment facilities.
See full RSA company page
